SCHEMBL14596153

SCHEMBL14596153

COc1cccc(S(=O)(=O)N(C)Cc2nc(NCCCN(C)C)c3ccccc3n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 4/20 0.55
POLB P06746 3/20 0.55
RXFP1 Q9HBX9 1/20 0.55
FLT3 P36888 5/20 0.53
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 2/20 0.48
TERT O14746 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
PDE5A O76074 1/20 0.47
TOP2A P11388 1/20 0.45
MERTK Q12866 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14596154 0.91 RAD52 (0.62) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596147 0.90 RAD52 (0.58) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596149 0.89 FLT3 (0.57) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596163 0.89 FLT3 (0.53) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596166 0.88 FLT3 (0.54) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596178 0.88 RAD52 (0.53) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596169 0.86 FLT3 (0.47) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596164 0.85 FLT3 (0.56) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596171 0.85 FLT3 (0.52) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596159 0.85 FLT3 (0.57) RAD52POLBRXFP1FLT3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment TP53, TP53BP1, ACIN1 RAD52 954/4885POLB 800/4885RXFP1 1985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.